Movement Disorder Market

Movement Disorder Market Outlook (2025 to 2035)

The global Movement Disorder market is expected to reach USD 2,697 Million by 2035, up from USD 801 Million in 2024. During the forecast period (2025 to 2035), the industry is projected to expand at a CAGR of 11.6%. Over the span of next ten years, the industry is poised to grow 3X with absolute dollar opportunity of USD 1,797.0 Million.

Movement disorders are a group of conditions that mainly cause dysfunction of motor functions with millions of people worldwide afflicted with diseases such as Parkinson’s disease, dystonia, and essential tremor. Deep brain stimulation, pharmacological therapies, and AI-driven diagnostics are improving patient outcomes.

Given the aging population combined with increasing prevalence, novel therapeutic approaches are needed to maximize mobility, independence and quality of life for those with the disease.

Metric	Value
Industry Size (2025E)	USD 900 Million
Industry Value (2035F)	USD 2,697 Million
CAGR (2025 to 2035)	11.6%

The movement disorder market encompasses a wide variety of neurological disorders- Parkinson’s disease, essential tremor, dystonia, Huntington’s disease and restless leg syndrome. These affect motor functions leading to uncontrollable movements or inability to control voluntary movements.

However, through increased awareness as well as the expansion of medical research, more patients are being diagnosed and treated successfully than ever before. Neurostimulation, gene therapy, and AI-based diagnostics (top of Form) Pharmaceutical companies, medical device manufacturers and research institutions are pursuing innovative therapies to intervene to treat these diseases.

There is a pressing need for effective treatment options, driving significant investments in this area and making movement disorders a hot target within the larger neurology market.

Rise in prevalence of diseases, technological advancements and increasing accessibility for healthcare are some factors estimated to foster the growth of movement disorder market. The aging population base is increasing the number of people suffering from neurodegenerative disorders which, in turn, is increasing the need for their treatment.

Emerging treatment techniques like deep brain stimulation, new drug treatments, personalized medicine, etc. will change the market landscape. Furthermore, drug development is accelerating via partnerships between pharmaceutical companies and R&D organizations.

There are significant opportunities in the movement disorder market indicating the continued investment of healthcare systems across the globe for the management of neurological disease aided with contributing innovative medical technology.

What impact does the rising aging population have on the Movement Disorder Market growth?

Global Movement Disorder Market growth drivers factors driving the market include an ageing global population, increased awareness of neurological conditions, and advancements in medical technology. Since screening methods have improved, there has been an increase in early diagnosis, allowing more patients to receive timely treatment.

Novel therapeutic approaches, such as drug development or neurostimulation therapies and robotic-assisted rehabilitation can optimize treatment effectiveness. And the pace of neurological research is receiving a further boost from government funding and private sector investments that are speeding drug approvals and therapeutic innovations.

Telemedicine and wearable technology for remote monitoring is expanding, which will lead to better patient outcomes and make movement disorder management more accessible and efficient everywhere in the world.

What are the latest market trends driving growth in the movement disorder treatment industry?

The market for movement disorders is quickly evolving with new approaches to classification driven by technology, particularly AI-based diagnostics and wearables for monitoring. Digital health solutions are critical in early diagnosis and tailored medical procedures. There’s also increasing interest in gene therapy and stem cell research, which focus on trying to modify the course of disease instead of just treating symptoms.

Step away from prescription meds: Some non-invasive brain stimulation techniques - such as transcranial magnetic stimulation - are emerging as alternatives to drug treatments. Another trend is the addition of virtual reality to rehabilitation programs, helping patients regain motor skills through active practice in a virtual setting.

What challenges hinder growth in the Movement Disorder Market, limiting treatment accessibility and innovation?

Their use in movement disorder management has expanded in recent years; however, the growth of this market is being curtailed by the high costs of treatment, limited access to advanced therapies in developing regions, and slow regulatory approvals for new drugs and devices-painting a picture of both growth and constraint in this market.

Many neurodegenerative diseases are still challenging to diagnose early on, resulting in delayed treatment and disease progression. The lengthy and costly drug discovery process restricts the risks of innovative therapeutics.

Moreover, side effects and complications associated with some existing treatments, such as deep brain stimulation or prolonged medication use, raise concerns not only for patients but also for the healthcare professionals who treat this population. To address these challenges, we must ensure greater investment in research, affordable treatment solutions, and in healthcare infrastructure.

What factors are driving the rapid growth of the rechargeable deep brain stimulator devices subsegment?

Rechargeable DBS devices constitute the fastest-growing subsegment within deep brain stimulator (DBS) devices. Rechargeable technology is a breakthrough advantage and offers several advantages compared to non-rechargeable DBS systems: longer battery life, fewer replacements, and improved control of stimulation for patients.

Most DBS devices are rechargeable, which last for up to 15 years compared to 3-5 years required for replacement of non-rechargeable devices. Because they reduce surgical risks and health care costs, thus preferred by patients and health professionals are they.

In addition, with the most modern DBS systems being rechargeable and based on advanced technology in the areas of batteries, wireless charging and smart programming features, the effectiveness of the treatment for all movement disorders including but not limited to Parkinson's disease, dystonia and essential tremor is further maximized.

There is a growing emphasis on patient comfort, long-term device efficacy, and reducing the need for hospital visits driving the increase of rechargeable DBS devices. This subsegment will expectedly generate a strong growth of the DBS market due to growing evolution of minimally invasive neuromodulation therapies.

What are the key regional market trends driving growth in the movement disorder treatment market?

Market for electrosurgery devices are highly concentrated in North America due to high healthcare expenditure and better facilities in the hospitals and surgical centers. The United States is the leading region in robotic-assisted and AI-driven surgeries, which is proliferating the demand for precision electrosurgical instruments. Further driving market growth are favorable reimbursement policies and the increasing uptake of minimally invasive processes.

East Asia is the fastest growing region, due to increased healthcare infrastructure, medical tourism, and rising demand for minimally invasive surgery (MIS) technology. China, Japan and South Korea are also investing heavily in laparoscopic and robotic-assisted surgeries, driven by a growing aged population. Market growth is also influenced by government initiatives and the expansion of private hospitals.

Western Europe has a significant presence with strong regulations, developed healthcare systems, and growing demand for surgeries. They're main adopter of energy based surgical devices are countries, including but not limited to, Germany, the UK, and France, investing in robotic surgery and AI driven medical innovations.

Conclusion & Future Outlook

The global electrosurgery devices market is anticipated to grow significantly until the year 2035 with increasing adoption of ultrasonic electrosurgery devices, technological advancements for electrosurgery devices, and rise in demand for minimally invasive procedures, according to the research analysis. It is anticipated that the market would expand at an impressive CAGR over the indicated time frame, offering prospective benefits for manufacturers and healthcare managers.

Driven by their accuracy & minimized complications, and combination with next-generation robotic & laparoscopic surgical systems as a complementary device, ultrasonic electrosurgery devices are the major growing subsegment in the high-growth long term that is expected to witness healthy growth throughout the forecast period.

The global landscape of electrosurgical devices will be changed by the strengthening healthcare infrastructure and the evolving regulatory approvals of advanced electrosurgical devices, further driving continued growth and broad acceptance in multiple surgical domains.

Shifts in the Movement Disorder Market from 2020 to 2024 and Future Trends 2025 to 2035

Looking ahead, the global market for movement disorders is expected to grow at an impressive CAGR in the forecast period of 2024 to 2030, on the back of increasing incidence of movement disorders, and growing number of patients requiring therapy and need for effective treatment options.

Market growth is mainly driven by an aging population, increased awareness, and advances in diagnostic tools. Important novel therapies, such as gene therapy and deep brain stimulation (DBS) have also received regulatory approvals that influenced the market landscape.

After all, the expected trends for 2025 to 2035 include, but are not limited to, artificial intelligence (AI) integrated diagnosis, treatment planning, neuroprotective therapies and broader precision medicine applications in terms of diagnosis capabilities and treatment options.

Higher compliance requirements, particularly for personalized treatments and biologics, will likely be imposed by regulators. Drug production and supply chain strategies will be scrutinized to ensure sustainability, and there will be a move towards production that is local and cost-effective.

Comparative Market Analysis

Market Shift	2020 to 2024
Regulatory Landscape	FDA and EMA approvals for novel movement disorder drugs, with a focus on symptomatic relief. Emphasis on safety and efficacy in DBS and gene therapy.
Technological Advancements	Introduction of gene therapy (e.g., adeno-associated virus-based treatments). Advancements in DBS, wearable sensors, and smartphone-based monitoring for Parkinson’s and dystonia patients.
Industry-Specific Demand	High demand from neurology clinics, hospitals, and research centers focusing on neurodegenerative disorders.
Sustainability & Circular Economy	Early-stage discussions on sustainable drug manufacturing and reduced environmental impact of medical devices.
Production & Supply Chain	Dependence on global supply chains for key drug components and medical devices. Challenges in raw material procurement due to COVID-19 disruptions.
Market Growth Drivers	Aging population, increased awareness, and early diagnosis. High investment in neurological research. Growing adoption of DBS therapy.

Market Shift	2025 to 2035
Regulatory Landscape	Stringent regulations on gene-editing therapies and neurostimulation devices. Enhanced guidelines for AI-driven diagnostics and personalized medicine.
Technological Advancements	AI-driven neurological diagnostics, non-invasive neuromodulation, and machine learning-based treatment customization. Expansion of precision medicine and biomarker-based therapies.
Industry-Specific Demand	Growth in demand from telemedicine providers, AI-driven diagnostics companies, and pharmaceutical firms investing in neurotherapeutics.
Sustainability & Circular Economy	Increased use of biodegradable materials in medical devices. Green chemistry principles in pharmaceutical production to minimize waste.
Production & Supply Chain	Shift towards localized drug production to mitigate geopolitical risks. AI-driven forecasting for raw material availability and just-in-time manufacturing.
Market Growth Drivers	Advancements in AI and big data for predictive diagnostics. Expansion of wearable and remote monitoring technologies. Increased funding for neurotherapeutic innovations and regenerative medicine.

Future Outlook (2025 to 2035)

There would be meaningful transformation for the movement disorder market and may occur due to high-impacting Harbingers of Neurology, these that fundamentally include breakthroughs in neurotechnology, AI-enabled personalized medicine and expanded clinical adoption of gene therapies.

There will be a transition from symptomatic management to the modification of disease, with pharmaceutical companies competing to develop curative therapies. The regulatory environment will also evolve to support new modalities while balancing patient safety and preventing innovation stifling.

At the same time, factors related to sustainability will influence how the industry approaches how to manufacture and how to distribute your product, with eco-friendly production processes at the forefront. The treatment market for movement disorders is poised for steady growth through 2035, buoyed by growing healthcare spending and a rising patient population.

Country-wise Outlook

United States Movement Disorder Industry Outlook

The US is still the strongest country in the movement disorder arena, with its high healthcare expenditure, advanced research infrastructure, and strong patient advocacy networks. That has not been the case in our country, where there are major funding sources for neurological research, especially for diseases like Parkinson’s disease, dystonia, and Huntington’s disease.

Today, there are state-of-the-art neurostimulation devices and AI-assisted diagnostics, expanding treatment options and improving outcomes. Furthermore, the U.S. pharmaceutical industry is extremely prolific in drug discovery and as such, there are many recent regulatory approvals for novel therapies.

The landscape of treatment is also evolving with the increasing use of deep brain stimulation (DBS) and of wearable monitoring technologies, which provide greater ability to tailor therapies to individual patients.

Germany Movement Disorder Industry Outlook

Germany is the European leader in movement disorder treatment, with comprehensive experience, a more mature legal framework, and a strong structure supporting medical and therapeutic innovation. The aging population in the country has led to increased demand for specialized neurological treatment, which has driven spending on advanced treatment options.

Patients are also benefitting greatly from government support of precision medicine and digital therapeutics and efforts from research institutions. Germany has made a great effort to integrate AI and machine learning in diagnostics to enhance early detection and treatment planning for movement disorders.

Furthermore, the pharmaceutical and biotechnology sectors within the country significantly contribute to a robust pipeline of neuropharmaceutical research and the availability of novel drug therapies.

Japan Movement Disorder Industry Outlook

One strong factor propelling growth in the movement disorder industry is Japan’s rapidly aging population, as neurodegenerative illnesses including Parkinson’s disease and essential tremor become more common. The German commitment to research into the neurological field remains high, with government sponsored research developing new therapies.

AI and robotics will play significant role in the development of rehabilitation solutions to support patients using non-invasive methods of symptom management. The Japanese pharmaceutical industry is, even more so, at the cutting edge of developing disease-modifying treatments, which includes a growing interest in gene therapies and regenerative medicine. Moreover, becoming digital health contributes to better monitoring of patients, leading to early intervention and personalized treatment approaches.

Country Wise Insights

Country	Attributes
United States (CAGR%)	11.3%
Germany (CAGR%)	10.8%
Japan (CAGR%)	11.0%

Category-Wise Market Outlook

By Product Type - Rechargeable Deep Brain Stimulator Devices

Rechargeable Deep Brain Stimulator (DBS) devices have the highest-growth in this segment as they provide longer battery life and the frequency of replacement surgery is lower. This advancement has proven to be economically advantageous in the long run while enhancing patient comfort by avoiding the need for high-risk surgical battery replacements.

Neuromodulation techniques have become more powerful and effective with developments of efficient rechargeable DBS devices and advanced stimulation control for Parkinson’s disease, dystonia, and essential tremor. Moreover, growing awareness among patients and physicians about the advantages of rechargeable systems over other alternatives is further propelling their adoption.

By End User - Ambulatory Surgical Centers

Among end users, Ambulatory Surgical Centers (ASCs) are the fastest growing segment thanks to a growing preference for outpatient minimally invasive procedures. ASCs are a lower-cost alternative to hospital-based care, with shorter lengths of stay and lower costs overall to the healthcare system.

Advances in deep brain stimulation technology and surgical techniques have made an increasing number of them appropriate for the ASC setting. The growth in the number of ASCs in the movement disorder market is also propelled by their better convenience, efficiency, and greater focus on the trend of outpatient neurological treatment.

By Application - Parkinson’s Disease

On the basis of Application, the market is segmented into Parkinson's Disease, Tremors, and Dystonia, with the Parkinson's Disease subsegment expected to grow rapidly in the forecast period owing to the rising incidence of the disease and the increasing adoption of deep brain stimulation procedures for the treatment of various movement disorders.

For patients with Parkinson’s disease, motor function deterioration becomes an important component which can often be alleviated by through the use of DBS therapy therefore making it the next line choice for patients who do not respond positively to medication.

The demand is driven by the advancements in neurostimulation technology and increasing awareness among healthcare professionals and patients regarding the advantages offered by DBS. Supportive healthcare policies and increasing research on movement disorders continue driving DBS usage for Parkinson’s disease treatment.

Competitive Analysis

In the forecast period, the global movement disorders market would grow significantly owing to the rising number of people suffering from conditions like Parkinson's disease, essential tremors, and dystonia. It is an era of particular technology for deep brain stimulation (DBS), wearable monitoring devices and gene therapies, which are improving patient outcomes and providing new options for the treatment of neuropsychiatric disorders.

In neurology discovery and drug development, cash is flooding in, and fresh generations of products and neuromodulation devices are now hitting the market. Such innovation therapies get approved via different regulatory pathways, enabling commercialization and promoting increased comfort and effectiveness of treatment, which in turn is likely to support the growth of the market.

With mergers and acquisitions on the rise, the market is also consolidating even more, allowing the biggest players to broaden their portfolios, increase their geographical coverage, and bring in new technologies. As competition in the health tech explosion grows, these companies are also aligning for innovation, strategic partnerships, and staying patient-centric to maintain their leading position in the burgeoning market.

Key players in the Movement Disorder Market are AbbVie Inc., Boston Scientific Corporation, Medtronic plc, GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Teva Pharmaceutical Industries Ltd., UCB S.A., Eisai Co., Ltd., Merz Pharmaceuticals.

As they are going to expend a part of their income (return from investments) on R&D, they are always going to look forward to purchasing solutions of the problems which will attract new customers towards them and give them an upper edge than the other competitors. These companies bring specialized services to a particular niche market, and performing this allows them to be distinct from the second kind of companies because they can learn and innovate while being in the business.

Company Name	Estimated Market Share (%)
Top 5 players	~60 - 65%
Tier II players	~15 - 20%
Others	~10 - 15%

Key Company Offerings and Activities

Company Name	Key Offerings/Activities
AbbVie Inc.	Develops advanced therapeutics for Parkinson’s disease and other movement disorders. Focuses on targeted drug delivery and next-generation pharmaceuticals.
Boston Scientific Corporation	Specializes in deep brain stimulation (DBS) and neurostimulation devices for movement disorders. Expanding minimally invasive treatment options.
Medtronic plc	Market leader in DBS technology for Parkinson’s and dystonia. Focuses on AI-integrated neuromodulation and adaptive stimulation systems.
GlaxoSmithKline plc	Invests in neurology-focused drug development, including gene therapies and small-molecule treatments for movement disorders.
Pfizer Inc.	Develops pharmaceutical treatments targeting Parkinson’s and neurodegenerative conditions. Exploring precision medicine and biomarker-driven therapies.
Novartis International AG	Offers neurology and movement disorder treatments, including innovative gene therapy and regenerative medicine approaches.
Teva Pharmaceutical Industries Ltd.	Specializes in generic and branded treatments for Parkinson’s disease and other movement disorders. Focused on drug reformulation and novel delivery systems.
UCB S.A.	Develops dopamine agonists and symptomatic treatments for Parkinson’s and epilepsy-related movement disorders. Investing in next-generation neurology solutions.
Eisai Co., Ltd.	Focuses on drug discovery for neurodegenerative diseases, including innovative approaches to motor symptom management.
Merz Pharmaceuticals	Leading provider of botulinum toxin therapies for dystonia and spasticity. Developing next-gen formulations for long-lasting symptom relief.

Key Company Insights

AbbVie Inc.

AbbVie - a comprehensive small molecule and antibody company who is heavily invested in the development of innovative therapies for movement disorders including Parkinson’s disease and other neurodegenerative disease - a strategic move to dominate the movement disorder space.

Focusing on novel drug delivery platforms and targeted therapeutics to address symptoms and improve outcomes. AbbVie is focused on the pipeline development of next-generation therapies that provide improved efficacy and improved safety; the latter further underscoring AbbVie’s ongoing commitment to shaping the future of care in the field of neurology.

Boston Scientific Corporation

Through its advanced deep brain stimulation (DBS) systems, particularly for Parkinson's disease and essential tremors, Boston Scientific is quickly penetrating the movement disorder market. Well known for its focus on minimally invasive treatment approaches, the company enables patients to manage symptoms with less surgical risk.

Boston Scientific is one of the companies exploring neuromodulation advances via partnerships with academic institutions and research centers, seeking new approaches to optimize therapy and improve long-term outcomes for patients.

Medtronic plc

With the largest share of the deep-brain stimulation market, Medtronic has greater neurostimulation experience than any other company. It is pouring resources into adaptive DBS systems, so that therapy adapts to real-time brain activity, making treatments more effective for each patient.

Expansion of International Partnerships with Neuroscience Institutes: Medtronic is harnessing partnerships with neurology research centers outside the U.S. to establish itself as a leader in the space of neuromodulation and treatment of movement disorders.

GlaxoSmithKline plc

GSK focuses on developing drugs for movement disorders as well as other diseases such as neurodegeneration. That has opened up new possibilities such as gene therapy, and developing small-molecule drugs to tackle the underlying causes of conditions like Parkinson’s disease, which the company is pursuing with a novel protein-degrading platform licensed from Novartis.

GSK's emphasis on precision medicine and biomarker-driven therapies reflects its dedication to developing more potent and personalized treatment options within the neurology space.

Other Key Market Players

Emerging companies and smaller players are fueling technology and competition in the movement disorder market. NeuroDerm is leading the way with new technologies in continuous drug delivery systems for Parkinson’s disease, helping people to receive the best effective invasion of their treatment with the greatest ease and convenience.

Alterity Therapeutics, developing first-in-class treatments for the neurodegeneration that underlies movement disorders. Cala Health, the company is developing non-invasive wearable therapies for the management of essential tremor, as an alternative to pharmacological and surgical treatment.

This technique has the potential to be an effective, non-invasive option to deep brain stimulation, and Insightec is pursuing it as the way to treat patients with a less invasive approach. These companies, together with other emerging innovators in the space, are instrumental in increasing available treatments and enriching the overall landscape of movement disorder care.

• On February 24, 2025, Medtronic received FDA approval for its BrainSense Adaptive Deep Brain Stimulation (DBS) system, a breakthrough technology designed for Parkinson’s disease patients. This system dynamically adjusts stimulation based on real-time brain signals, enhancing personalized therapy and symptom management. It marks a significant advancement in neuromodulation.
• In February 2025, Supernus Pharmaceuticals received FDA approval for Onapgo, a drug-device combination that delivers continuous subcutaneous apomorphine to help manage Parkinson’s disease symptoms, including motor fluctuations. This innovative therapy provides an alternative for patients experiencing "off" episodes, enhancing symptom control and improving quality of life.

Conclusion

We shall discuss the advances in our understanding of movement disorders and dive deeper into the role of AI and machine learning in diagnostics and personalized therapy in the movement disorder market. Such technologies are allowing for better disease detection, real-time symptom monitoring, and customized adjustments of treatments based on individualized patient data.

The non-invasive neuromodulation techniques are increasingly being sought after as alternatives to DBS surgery as it causes patients to seek less invasive treatment solutions with lower risks and side effects. Genetic and biomarker analysis has progressed to the point where tailored treatment regimens are becoming increasingly possible, and personalized medicine is gaining traction.

Moreover, regulatory approvals in the Asia-pacific and Latin America regions are increasing market access and facilitating worldwide expansion, while providing access to innovative therapies in over-the-counter markets. However, these trends are expected to influence the future of new treatments for movement disorders, expanding treatment alternatives and potentially enhancing patient outcomes as the industry continues to evolve.

Fact.MR has provided detailed information about the price points of key manufacturers of Movement Disorder Market positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

Segmentation of Movement Disorder Market Research

• By Product Type :

  • Rechargeable Deep Brain Stimulator Devices
  • Non-rechargeable Deep Brain Stimulator Devices

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics

• By Application :

  • Parkinson's Disease
  • Essential Tremor
  • Dystonia
  • Refractory Epilepsy
  • Obsessive Compulsive Disorder

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa